Structural property and risk assessment of loose deposits in drinking water distribution systems

Discoloration events caused by loose deposits resuspension in drinking water distribution systems (DWDS) are main aspects of customer complaints across the world, but the understanding of the potential risks of loose deposits is insufficient. In this study, loose deposits in real DWDS were collected from regions frequently experiencing ‘yellow water’. Cytotoxicity of healthy human liver cells was used to evaluate the toxicity risks of the particle samples. The results showed that the loose deposits would have a realistic discoloration risk (turbidity > 10 NTU) when their concentrations were higher than 10 mg/L. The water sample containing 1,000 mg/L loose deposits had dark yellow color (100–300 PCU) and cytotoxicity (viability of human liver cells during cytotoxicity tests 59.18–80.69%), while the water sample containing 1 mg/L loose deposits did not have obvious color (<15 PCU) and cytotoxicity (>97.00%). Particle size showed a stronger correlation with relative viability (r = 0.761) than other properties (specific area, metal content, contact angle, saturation magnetization and electron transfer number). However, it is interesting to notice that both turbidity and color had a low correlation with relative viability, thus the toxicity of the particles could not be properly judged using turbidity or color. This study gives an important guidance that though the loose deposits could be visualized during water discoloration, its toxicity risks could not be evaluated through aesthetic indicators.

Tenascin C Promotes Glioma Cell Malignant Behavior and Inhibits Chemosensitivity to Paclitaxel via Activation of the PI3K/AKT Signaling Pathway

The present study aimed to detect the effect of tenascin C (TNC) on cell function and chemosensitivity to paclitaxel and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling in glioma cells.Human glioma cells U87, LN-229, T98G and U251 and normal human astrocytes were obtained, in which TNC expression was detected. The U87 cells and U251 cells were chosen and infected with lentivirus of control overexpression, TNC overexpression, control knockdown, and TNC knockdown for functional experiments. Rescue experiments were then performed to evaluate the effect of PI3K/AKT activator 740 Y-P on cell function and chemosensitivity to paclitaxel in TNC knockdown U251 cells. TNC mRNA and protein expression was elevated in glioma cells, including U87, LN-229, U251 and T98G cells, compared to normal human astrocytes. In U87 and U251 cells, TNC promoted proliferation while inhibiting apoptosis. In addition, TNC upregulated PI3K and p-AKT protein expression in U87 and U251 cells. As for chemosensitivity, TNC increased relative viability in U251 cells treated with 400 ng/mL and 800 ng/mL paclitaxel. In terms of stemness, TNC increased the sphere number per 1000 cells, CD44+CD133+ cell percentage and 1/stem cell frequency (assessed by extreme limiting dilution analysis) in U251 cells. In rescue experiments, 740 Y-P reduced the effect of TNC on proliferation, apoptosis, chemosensitivity to paclitaxel, and stemness in U251 cells. TNC acts as an oncogenic factor by promoting cancer cell proliferation and stemness while inhibiting apoptosis and chemosensitivity to paclitaxel in glioma via modulation of PI3K/AKT signaling.

Fusarium sp. L-Asparaginases: purification, characterization and potential assessment as anti-leukemic chemotherapeutic agent

Asparaginases play an important role in the treatment of leukemia. It is part of chemotherapy in the treatment of leukemia in the last three decades. L-Asparaginase isolated from Fusarium sp. isolated from soil and purified using ammonium sulfate precipitation and Sephadex G 100. Characterization of the crude enzyme revealed it is a metalloprotease inhibited by EDTA. Hg2+, Cd2+, and Pb2+ also inhibited the enzyme. Mg2+, Zn2+ and Ca2+ activated L. asparaginase. Further, the kinetic studies of purified enzyme were carried out. Vmax and Km and were 0.031 M and 454 U/mL, respectively. The optimum temperature was 30°C, optimum pH was 7. Concerning substrate specificity; gelatin and casein in addition to L-asparagine were tested. The enzyme was found to be non-specific, could hydrolyze all tested substrates at different rates. Maximum enzyme activity was recorded in the case of L-asparagine, followed by Casein and gelatin, respectively. The molecular weight of L-Asparaginase was 22.5 kDa. The Anti-leukemic cytotoxicity assay of the enzyme against RAW2674 leukemic cell lines by MTT viability test was estimated. The enzyme exhibited anti-leukemic activity with IC50 of 70 Uml− 1 and relative viability 70 % of control. The current work presents additional information regarding the purification and characterization of the enzyme produced by Fusarium sp. and its evaluation as a potential anti-leukemic chemotherapeutic agent.

Potential toxicity of leachate from the municipal landfill in view of the possibility of their migration to the environment through infiltration into groundwater

Leachate from landfills is a product of complex biological and physicochemical processes occurring during waste storage. In the present study, the toxicity of landfill leachate (LL) to human and bacterial cells was investigated for better understanding of LL environmental toxicity. Studies regarding LL physicochemical properties and cytotoxicity analysis were conducted. In Escherichia coli, Pseudomonas fluorescens, Bacillus subtilis, fibroblasts and melanoma A-375 cells, cell viability assays were applied. For the determination of LL antibacterial activity, twofold dilution series of LL were prepared in the range from 50% to 0.1% (50%, 25%, 12.5%, 6.25%, 3.13%, 1.56%, 0.78%, 0.39%, 0.2%, 0.1%). Human cells viability was examined at LL concentrations of 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 5%, 10%, 15%, 20% and 30%. ROS (reactive oxygen species) content and apoptosis level were also measured in bacterial and human cells under the influence of LL. Unexpectedly obtained results indicate stimulation of bacterial viability by LL. Fibroblasts under the influence of LL showed decrease in their viability and increase in apoptosis level and A-375 melanoma cells showed an increase in relative viability and decrease in apoptosis. ROS level in bacterial cells was elevated in higher LL concentrations and decreased in lower LL concentrations. In human cells, ROS content was rather high in both tested cell lines. Presented results indicate cytotoxic potential of analyzed LL and the necessity of LL monitoring because it may pose a health hazard for exposed human populations and the whole human environment.

Replication of a Dog-Origin H6N1 Influenza Virus in Cell Culture and Mice

The world’s first natural avian-origin H6N1 influenza A virus infection case in dogs was confirmed in Taiwan in 2014. The H6N1 virus in chickens has been endemic in Taiwan since 1972. Whether the dog H6N1 virus has interspecies transmission potential is the key issue we aim to understand. Following one virus passage in embryonated eggs and two further passages in MDCK cells, we obtained two virus derivatives, E01EE (PB1 739E and PB2 627E) and E01GK (PB1 739G and PB2 627K), respectively. The pathogenicity of E01EE and E01GK was investigated using plaque assay, growth dynamic analysis and cell viability quantification in cells from different animal species. The impact of amino acid mutation on PB1 739 and PB2 627 on viral ribonucleoprotein (RNP) activity was also analyzed. Further mouse infection experiments were performed. The results showed that both E01EE and E01GK decreased cell relative viability of canine MDCK cells, human A549 cells and chicken DF1 cells. E01Gk caused greater cellular harm in MDCK and A549 cells and had significantly higher virus titers in all of the cells compared to E01EE. The PB2 627K but not PB1 739G was the critical mutation that influenced the viral RNP activity. Both E01EE and E01GK caused mice pneumonia and considerable virus shedding, especially E01GK. This report verifies PB2 E627K mutation in virulence and spotlights the potential for the dog H6N1 virus to extend interspecies transmission.

Drug GRADE: an integrated analysis of population growth and cell death reveals drug-specific and cancer subtype-specific response profiles

ABSTRACTIn the pre-clinical evaluation of anti-cancer drugs, two different measurement approaches are used: relative viability, which scores an amalgam of growth arrest and cell death, and fractional viability, which more specifically scores the degree of cell killing. In this study, we directly quantify relationships between drug-induced growth inhibition and drug-induced cell death by counting live and dead cells over time using quantitative microscopy. We find that most drugs affect both growth and death, but with different proportions and with different relative timing. These features lead to a non-uniform and unpredictable relationship between the canonical relative and fractional drug response measurements. To unify these disparate measurements, we create a new data visualization and data analysis platform, called drug GRADE, which characterizes the degree to which cell death contributes to an observed reduction in population size for any given drug. Our new method reveals both drug- and genotype-specific drug responses, which are not captured using traditional pharmaco-metrics. Taken together, this study highlights the extremely idiosyncratic nature of drug-induced growth and cell death and provides a new analysis tool for quantitatively evaluating these behaviors.

ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL

The receptor tyrosine kinase ROR1 is uniquely expressed on and required for many hematological malignancies such as t(1;19) positive acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). The t(1;19) is one of the most frequent translocations in B-ALL, observed in both adult and pediatric patients. The translocation has intermediate prognosis on its own, but is associated with a poor prognosis in the unbalanced der(19)t(1;19) form in pediatric ALL, and in the context of hyperdiploid B-ALL. While leukemic cell dependence on ROR1 is known, ROR1 lacks kinase activity making it difficult to target therapeutically. However, we have previously shown that ROR1 can be targeted to deliver therapeutic payload specifically to leukemic cells in CLL, sparing the normal cells from toxic side effects. This encouraged us to develop ROR1 directed immunoliposomal nanoparticles encapsulating a novel small molecule OSU-2S. OSU-2S is a non-immunosuppressive derivative of the sphingosine analogue FTY720, with potent anti-tumor activity against multiple hematological malignancies including CLL, mantle cell lymphoma (MCL) and canine B-cell lymphoma. OSU-2S demonstrated potent dose dependent cytotoxicity in patient derived B-ALL samples with different cytogenetic backgrounds including translocations t(4;11), t(9;22) and t(1;19) as well as hyperdiploid, hypodiploid and normal cytogenetic background [n=7, p= 0.0032 (0 vs 2.5µM), mean decrease in relative viability= 44.51±12.12%] as assessed by Annexin V/Propidium Iodide staining. We confirmed ROR1 expression on t(1;19) translocated patient samples by flow cytometry, and synthesized ROR1 targeted OSU-2S immunoliposomal nanoparticles (2A2-OSU-2S-ILP) (mean size= 186.9 +/- 0.8 nm, mean concentration= 1.38*1013 particles/ml). 2A2-OSU-2S-ILP was selectively cytotoxic to t(1;19) translocated ALL, including unbalanced der(19)t(1;19), from relapsed patients aged 29-37, but not ROR1-ve, t(1;19) non translocated ALL, as compared to control IgG-OSU-2S-ILP, or 2A2/IgG immunoliposomes without OSU-2S [n=3, p= 0.04, mean decrease in relative viability (IgG-OSU-2S-ILP vs 2A2-OSU-2S-ILP)= 35.14±7.36%]. Similar results were seen in ROR1+ve 697 cells, a B-ALL cell line carrying t(1;19) translocation, where 2A2-OSU-2S-ILP showed selective cytotoxicity [n=8, p=0.004, mean decrease in relative viability (IgG-OSU-2S-ILP vs 2A2-OSU-2S-ILP)= 61.62±14.63%]. To assess the effect of 2A2-OSU-2S-ILP on t(1;19) positive ALL in-vivo, we used a disseminated cell line derived xenograft model. Immunocompromised NSG mice were engrafted with 697 cells, treated with 2A2-OSU-2S-ILP or IgG-OSU-2S-ILP for 14 days and tumor burden was assessed in the spleen and bone marrow. 2A2-OSU-2S-ILP treatment significantly reduced the number of human CD45+CD19+ cells in the bone marrow as compared to IgG-OSU-2S-ILP cohort (n=6 per cohort, p=0.022, mean decrease in 697 cells in marrow= 1.751 ± 0.6372 million cells/ femur). There was also a trend towards decreased tumor burden in spleen (mean decrease in 697 cells in spleen= 1.883 ± 0.9729 million cells). Together, these data show the ability of ROR1 targeted liposomal nanoparticles to selectively deliver its payload to leukemic cells in t(1;19) translocated B-ALL, sparing toxicity to the normal cells. Ongoing studies are directed towards understanding the mechanistic basis of OSU-2S mediated therapeutic benefit in B-ALL in-vitro and in-vivo. [This work was supported by NIH-R01-CA197844-01. SG is supported by Pelotonia Graduate Fellowship] Disclosures Baskar: NIH: Patents & Royalties: ROR1 mAb 2A2. Rader:NIH: Patents & Royalties: ROR1 mAb 2A2. Byrd:Janssen: Consultancy, Other: Travel Expenses, Research Funding, Speakers Bureau; Gilead: Other: Travel Expenses, Research Funding, Speakers Bureau; Genentech: Research Funding; TG Therapeutics: Other: Travel Expenses, Research Funding, Speakers Bureau; BeiGene: Research Funding; Ohio State University: Patents & Royalties: OSU-2S; Acerta: Research Funding; Novartis: Other: Travel Expenses, Speakers Bureau; Pharmacyclics LLC, an AbbVie Company: Other: Travel Expenses, Research Funding, Speakers Bureau. Bhatnagar:Novartis and Astellas: Consultancy, Honoraria; Cell Therapeutics, Inc.: Other: Research support; Karyopharm Therapeutics: Other: Research support. Muthusamy:Ohio State University: Patents & Royalties: OSU-2S.

Development and Evaluation of an Injectable Chitosan/β-Glycerophosphate Paste as a Local Antibiotic Delivery System for Trauma Care

Complex open musculoskeletal wounds are a leading cause of morbidity worldwide, partially due to a high risk of bacterial contamination. Local delivery systems may be used as adjunctive therapies to prevent infection, but they may be nondegradable, possess inadequate wound coverage, or migrate from the wound site. To address this issue, a thermo-responsive, injectable chitosan paste was fabricated by incorporating beta-glycerophosphate. The efficacy of thermo-paste as an adjunctive infection prevention tool was evaluated in terms of cytocompatibility, degradation, antibacterial, injectability, and inflammation properties. In vitro studies demonstrated thermo-paste may be loaded with amikacin and vancomycin and release inhibitory levels for at least 3 days. Further, approximately 60% of thermo-paste was enzymatically degraded within 7 days in vitro. The viability of cells exposed to thermo-paste exceeded ISO 10993-5 standards with approximately 73% relative viability of a control chitosan sponge. The ejection force of thermo-paste, approximately 20 N, was lower than previously studied paste formulations and within relevant clinical ejection force ranges. An in vivo murine biocompatibility study demonstrated that thermo-paste induced minimal inflammation after implantation for 7 days, similar to previously developed chitosan pastes. Results from these preliminary preclinical studies indicate that thermo-paste shows promise for further development as an antibiotic delivery system for infection prevention.

Extractive Fermentation of Ethanol from Sweet Sorghum Using Vacuum Fractionation Technique: Optimization and Techno-Economic Assessment

Direct extraction of high purity ethanol from fermentation broth was investigated using a vacuum fractionation technique. Batch and repeated-batch extractive fermentation of ethanol were carried out using concentrated sweet sorghum as a carbon source. The effect of product inhibition was reduced by continuous removing ethanol from the fermented broth. About 60 % relative viability was observed in fermented broth with a higher productivity value. Due to the high value of living cells presented in the medium, repeated-batch extractive fermentation was subsequently performed. The ethanol was continuously fractionated out from the system at the average rate of 10.2 g/h with the concentration of approximately 80 wt%. There were 8 cycles of fermentation using only 1 time inoculation. Nevertheless, the calculated ethanol productivity and relative viability for each fermentation cycle were decreased gradually due to the accumulation of toxic substances in fermented broth. The simulation of 200 liters continuous extractive fermentation system using ASPEN PLUS was studied including process optimization and economical consideration. 18.5 liters of ethanol solutions 82 wt% with insignificant amounts of by-product was produced from a 200 liters extractive fermentation system per day. Production cost including raw material and utilities cost was approximately 0.71 €/liter. The economic and systemic performance process were subsequently analyzed, and including that ethanol loss was recovered using a gas scrubber connected to the vapor exiting the venturi tank as well as in the stillage stream. The calculated utility costs after process modification were 0.5 €/liter of ethanol, approximately 30 % of production cost was reduced.